BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

iPierian Inc. to Present at Future Leaders in the Biotech Industry Conference


4/12/2011 9:04:36 AM

SOUTH SAN FRANCISCO, CA--(Marketwire - April 12, 2011) - iPierian Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, announced today that Michael C. Venuti, Ph.D., chief executive officer, will present at the Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center, New York, New York. Their presentation will take place on Friday, April 15, 2011, at 11:30 a.m., Eastern Daylight Time. Dr. Venuti will present an overview of iPierian and discuss the company's discovery platform, therapeutic pipeline, business strategy and upcoming milestones.

About iPierian
iPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and the discovery and development of innovative therapeutics using patient-derived cells as models of human disease. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success by using precise human disease models to develop proprietary small molecule or biologic therapeutics. The initial therapeutic focus of the company is neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, as well as type 2 diabetes.

The company's Scientific Advisory Board (SAB) is comprised of leading researchers and authorities in the stem cell field, including individual investigators from the Harvard Stem Cell Institute, The Gladstone Institute of Cardiovascular Disease, The University of California, San Francisco (UCSF), and Kyoto University. Our SAB members include George Q. Daley, M.D., Ph.D., Douglas A. Melton, Ph.D., and Lee L. Rubin, Ph.D. all of the Harvard Stem Cell Institute, Deepak Srivastava, M.D., of The Gladstone Institute of Cardiovascular Disease and UCSF, and Shinya Yamanaka, M.D, PhD., of Kyoto University, the Center for iPS Cell Research and Application (CiRA), and The Gladstone Institute of Cardiovascular Disease.

iPierian is located in South San Francisco, California. For more information, please visit www.ipierian.com.


Contacts:
Danielle Bertrand
WCG
415-946-1056
Email Contact

Matthew Plunkett
iPierian
650-872-4745



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES